Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 40 clinical trials
A Phase I Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

To explore the DLT of ZG0418 for Patients with Advanced ALK+ or ROS1+ NSCLC And Previously Treated with Chemotherapy or Crizotinib, and to determine the MTD or the R2PD.

measurable disease
proto-oncogene tyrosine-protein kinase ros
lung carcinoma
crizotinib
neutrophil count
  • 0 views
  • 25 Jan, 2021
  • 1 location
A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

has been receiving treatment with a targeted biological agent such as erlotinib, crizotinib, or other drugs.

lymphoma
erlotinib
epidermal growth factor receptor
brain metastases
anaplastic lymphoma
  • 0 views
  • 16 Feb, 2021
  • 1 location
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety

cancer
malignant melanoma of skin
measurable disease
solid tumour
  • 36 views
  • 26 Feb, 2021
  • 8 locations
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

ceritinib and trametinib in 3 single arm cohorts: ALKi (ALK inhibitor) nave patients; post-crizotinib progressed disease (PD) patients; and PD second line ALK tyrosine kinase inhibitor (TKI) patients.

lung carcinoma
metastasis
alectinib
brigatinib
potassium
  • 24 views
  • 25 Jan, 2021
  • 3 locations
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive or ROS1-positive Non-small Cell Lung Cancer

The purpose of the study is to evaluate safety and efficacy of WX-0593 oral tablets in ALK -positive, or ROS1-positive non-small cell lung cancer (NSCLC)

  • 0 views
  • 28 Jan, 2021
  • 41 locations
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Lung cancer remains the most lethal malignancy in both sexes around the world. It is estimated that lung cancer caused 234,030 deaths in the United States in 2016, accounting for 28% of all cancer-related deaths. In 2012 alone, a total of 6,697 deaths from lung cancer were registered in Mexico; …

  • 0 views
  • 18 Feb, 2021
  • 1 location
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.

ifosfamide
cytarabine
fludarabine
etoposide
cancer
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations following targeted therapies.

  • 0 views
  • 26 Jan, 2021
  • 23 locations
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.

  • 0 views
  • 14 Feb, 2021
  • 1 location
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs …

measurable disease
kinase inhibitor
lung carcinoma
progressive disease
alopecia
  • 0 views
  • 24 Jan, 2021
  • 4 locations